2016 SPEAKER BIOS
Michelle is a partner in the Business Department of Nutter, a member of the firm’s Emerging Companies practice group and chair of the Life Sciences practice group. Michelle’s practice focuses on corporate and securities law, including angel and venture capital transactions, public securities offerings, mergers and acquisitions, strategic partnerships and collaborations, licensing, distribution transactions and corporate governance, and equity compensation matters. Michelle represents both emerging and commercialized life sciences companies that are private, public, or planning to make a public offering. She serves as outside general counsel to companies in biotechnology, medical devices, diagnostics, and health care services. Michelle received her B.A. and J.D. from the University of California, Berkeley. Michelle is a member of or participates at Boston Harbor Angels, MTTC, Launchpad Venture Group, MassBio and MassMEDIC.
Chuck brings over 20 years of experience in medical device development to BionX. He has vast experience as a clinician, med-tech executive and CEO. He has had the opportunity to introduce a number of breakthrough technologies that have changed healthcare, navigating the clinical, regulatory and reimbursement challenges along the way. Before joining BionX, Chuck was founder and CEO of Ninepoint Medical, a developer of medical devices that enable high resolution in-vivo imaging. At NinePoint, he brought together an outstanding team who developed and launched the first product within 3 years of licensing the fundamental technology from MGH. Prior to that, Chuck was Executive Vice President and Chief Medical Officer of Novasys Medical, Inc., where he was responsible for the successful launch of a device to treat stress urinary incontinence. Prior to Novasys, he was Chief Medical Officer at Boston Scientific, and Vice President of clinical research and medical affairs at Conceptus. Chuck has served on committees of the U.S. Food and Drug Administration, Centers for Medicare & Medicaid Services, the World Health Organization, the United Nations, and the U.S. Agency for International Development. Chuck trained in general surgery at Columbia-Presbyterian Medical Center. He earned his undergraduate degree from Yale University and his MD degree from the College of Physicians and Surgeons of Columbia University.
Steve is the Vice President of Zaffre Investments, a wholly owned strategic investment subsidiary of Blue Cross Blue Shield of Massachusetts. Steve provides strategic, consultative and business development support to the Zaffre portfolio companies. Steve serves as a Senior Advisor to the Chief Executive Officer in his work with the National Blue Cross Blue Shield Association as well as strategic opportunities across the Blues System. Steve serves as a senior liaison to other Blue Plans as well as helping to lead in the development and evaluation of investment opportunities.
Steve was appointed by Governor Deval Patrick and reappointed by Governor Charlie Baker to the Commonwealth’s Health Information Technology Council as the insurance industry representative. Steve has represented BCBSMA on prior health care policy commissions appointed by Governor Patrick. Steve also participates on several national policy and advisory groups with the Blue Cross Blue Shield Association in Chicago. Steve is a Director of the Massachusetts eHealth Collaborative, the Massachusetts Health Data Consortium and the Wilmington (Mass) Youth Lacrosse Association. Steve is currently President of the Board at the Boston-based Children’s Investment Fund and Board Observer for Zaffre Portfolio companies lifeIMAGE and InformedDNA. Steve is also a US Lacrosse certified coach.
Steve is a graduate of the University of Miami; Coral Cables FL. Steve also received his Certified Healthcare Insurance Executive (CHIE) professional designation from America’s Health Insurance Plans (AHIP) Executive Leadership Program in 2012.
Michael is a General Partner and Co-founder of Flare Capital Partners, an early-stage healthcare technology venture capital firm. Some of his existing and prior board seats include Circulation, Explorys, HealthVerity, Iora Health, Predilytics, Taris, T2 Biosystems and Welltok.
Michael currently serves as chairman of the Entrepreneurship Committee of the Massachusetts Information Collaborative and on the Investment Committee for the Partners Innovation Fund and Massachusetts Eye & Ear Infirmary. Michael also serves on the Industry Advisory Board of the Cleveland Clinic and Boston Children’s Hospital, as well as serving on several other boards including the New England Investors’ Committee of Capital Innovation. He was the former chairman of the New England Venture Capital Association and on the Executive Committee of the board of the National Venture Capital Association. Michael earned a B.A. with honors in chemistry from Williams College and an M.B.A. from Harvard Business School.
Luba Greenwood is Vice President of Global Mergers & Acquisitions and Business Development at F. Hoffmann-La Roche Ltd, Diagnostics. She brings pharmaceutical and biotechnology industry experience and expertise in building and advising innovative technology companies and providing strategic counsel to global corporations. Her career has spanned leadership roles in venture investing, business development, M&A, law, consulting, and operations, with positions at Pfizer, Pronutria (now Axcella Health), and most recently Colt Ventures, where she served as a Venture Partner. Luba began her career practicing law where she represented large multinational corporations, start-ups, and private equity and venture capital funds in biotechnology, high technology, energy, and finance industries in securities, intellectual property, regulatory, and litigation matters. Luba is an active member of the community, teaching at Boston University School of Management and Boston University Law School, serving on boards of the Longwood Symphony Orchestra, and co-chairing MassBio’s Entrepreneur’s University. She is also an active mentor and judge for entrepreneurship initiatives, including the MIT 100K Entrepreneurship Competition and MassChallenge.
Jeremy’s practice focuses on emerging companies, private equity, venture capital and angel financing transactions, mergers and acquisitions, executive and team compensation matters, and general start-up support. Serving as Nutter’s entrepreneur-in-residence, Jeremy works on strategy and corporate development matters with investors and executives in life sciences, technology, and food and beverage industries. Jeremy is an active angel investor and is a member of the board of The Capital Network and serves on the Advisory Board of the MBI Health Program. He is a long-time mentor at MassChallenge and LearnLaunch, an expert advisor at the Innovation Hub at Brigham and Women’s Hospital, and is a speaker, reviewer, judge or mentor for MIT HackingMedicine, HackingPediatrics, the Mass Tech Transfer Center, the Mass Life Science Center, and Startup Institute.
Vice President | Noveome, Inc./Board Member, The Michael J. Fox Foundation for Parkinson's Research
Skip Irving has 35 years of experience advising companies on business strategy, product commercialization, R&D planning and business development in the biotech, pharmaceutical and medical products industries. Previously, he was a Managing Director at Health Advances, a leading life-science focused management consulting firm. Skip led commercial development at the Massachusetts Biotechnology Research Institute and a directed worldwide healthcare consulting at Arthur D. Little. He also helped to found and served on the Board of ViaCell.
Dr. Olle is a co-founder and Chief Executive Officer of Vedanta Biosciences. He has been a member of the founding teams of four companies of the PureTech portfolio and serves as a member of the Board of Directors of Vedanta Biosciences and Follica Biosciences. In 2013, Dr. Olle was named “Innovator of the Year” in MIT’s Technology Review, Spain’s “Innovators under 35” awards, and in 2015 he was awarded the Princess of Girona business award by the King of Spain. He completed his doctoral work at the Chemical Engineering Department at MIT, where he developed a novel method for large scale bacterial culture. During his graduate work, Dr. Olle was awarded the “la Caixa” fellowship. Dr. Olle received his B.Eng. In Chemical Engineering from Universitat Rovira i Virgili, Spain, his M.S. and Ph.D. in Chemical Engineering Practice from MIT, and his MBA from the MIT Sloan School of Management. He has published his work in journals including Nature and Nature Biotechnology.
Travis Wilson is an investment partner at Gurnet Point Capital, a Boston-based $2 billion healthcare and life sciences fund focused on growth equity and venture opportunities worldwide. Previously, he was the President and CEO of Stealth BioTherapeutics, a late-stage clinical biotechnology company developing therapies to treat mitochondrial dysfunction in common and rare diseases. Travis has extensive experience in leading biotechnology companies and venture investing, heading transactions from seed-investments to commercial assets. For more than a decade, he was a member of the investment team at Morningside Ventures, an international firm dedicated to life science and technology startups. With Morningside, he worked on multiple financings, including several public and private biotechnology companies such as Chimerix (NASDAQ: CMRX), Genocea (NASDAQ: GNCA), BioVex (acquired by Amgen), Aduro (NASDAQ: ADRO) and Argos (NASDAQ: ARGS). Travis also served as a director and board member for nonclinical and clinical stage companies, providing operational and management support to a portfolio of companies developing technologies across a broad spectrum of therapeutic focus, including orphan diseases, cardio-renal disorders, oncology, cell-therapy and ophthalmology. He has lectured extensively on life sciences investing and management, and is a long-time supporter of patient-advocacy groups including the United Mitochondrial Disease Foundation and National Organization for Rare Disorders. Travis holds a law degree and a chemical engineering degree, both from the University of Wisconsin.